Additionally, we compared biologically relevant parameters, e.g., hormone receptor status, grade, tumor proliferation (Ki-67), and stromal tumor-infiltrating lymphocytes (sTILs) between the HER2-low and HER2-zero tumors. The gene discussed is ERBB2; the disease is neoplasm.